- Home
- PAII vs AMRN Comparison
PAII vs AMRN Comparison
Compare PAII & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAII
- AMRN
- Stock Information
- Founded
- PAII 2025
- AMRN 1989
- Country
- PAII United States
- AMRN Ireland
- Employees
- PAII N/A
- AMRN N/A
- Industry
- PAII
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PAII
- AMRN Health Care
- Exchange
- PAII Nasdaq
- AMRN Nasdaq
- Market Cap
- PAII 271.3M
- AMRN 302.0M
- IPO Year
- PAII 2025
- AMRN 1993
- Fundamental
- Price
- PAII $9.95
- AMRN $19.29
- Analyst Decision
- PAII
- AMRN Strong Sell
- Analyst Count
- PAII 0
- AMRN 1
- Target Price
- PAII N/A
- AMRN $12.00
- AVG Volume (30 Days)
- PAII 229.1K
- AMRN 90.2K
- Earning Date
- PAII 01-01-0001
- AMRN 10-29-2025
- Dividend Yield
- PAII N/A
- AMRN N/A
- EPS Growth
- PAII N/A
- AMRN N/A
- EPS
- PAII N/A
- AMRN N/A
- Revenue
- PAII N/A
- AMRN $219,361,000.00
- Revenue This Year
- PAII N/A
- AMRN N/A
- Revenue Next Year
- PAII N/A
- AMRN N/A
- P/E Ratio
- PAII N/A
- AMRN N/A
- Revenue Growth
- PAII N/A
- AMRN N/A
- 52 Week Low
- PAII $9.92
- AMRN $7.08
- 52 Week High
- PAII $9.97
- AMRN $20.43
- Technical
- Relative Strength Index (RSI)
- PAII N/A
- AMRN 84.19
- Support Level
- PAII N/A
- AMRN $15.24
- Resistance Level
- PAII N/A
- AMRN $15.74
- Average True Range (ATR)
- PAII 0.00
- AMRN 0.78
- MACD
- PAII 0.00
- AMRN 0.44
- Stochastic Oscillator
- PAII 0.00
- AMRN 79.69
About PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares
Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.